XAF 5

Drug Profile

XAF 5

Alternative Names: XAF-5; XOPH5

Latest Information Update: 25 Apr 2016

Price : $50

At a glance

  • Originator Harvard Medical School
  • Developer Allergan
  • Class Small molecules
  • Mechanism of Action Adipocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Subcutaneous fat disorders

Most Recent Events

  • 21 Apr 2016 Topokine Therapeutics has been acquired and merged into Allergan
  • 26 Feb 2016 Topokine Therapeutics suspends enrolment in a phase IIa trial for Subcutaneous fat disorders (excess submental fat) in USA (NCT01990326)
  • 01 Jan 2016 Phase-II/III clinical trials in Subcutaneous fat disorders (lower lid steatoblepharon in adults and the elderly) in USA (Topical, ointment) (NCT02607683)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top